Infinity Pharma $INFI ASCO presentations

Infinity Pharma will make several presentations at ASCO:


Saturday June 4th: Poster Presentation
Abstract #3014
"A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors."
Charles M. Rudin, MD, PhD

Saturday June 4th: Poster Presentation
Abstract #4114
"The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer."
Joe Stephenson, MD

Monday June 6th: Poster Presentation
Abstract #590
"Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer."
Shanu Modi, MD

Monday June 6th: Poster Presentation
Abstract #7516
"Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC)."
Gregory J. Riely, MD, PhD

Note: I could not locate any presentations regarding INFI's second HSP90 inhibitor IPI-493